NCT01918254 - A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 6, 2013

Primary Completion Date

October 7, 2016

Study Completion Date

October 7, 2016

Conditions

Breast Cancer

Interventions

DRUG

Paclitaxel

Paclitaxel IV infusion will be administered as per schedule described in individual arm.

DRUG

Pertuzumab

Pertuzumab IV infusion will be administered as per schedule described in individual arm.

DRUG

Lumretuzumab

Lumretuzumab will be administered as per schedule described in individual arm.

Trial Locations (13)

2100

Rigshospitalet, Onkologisk Klinik, København Ø

14076

Centre Francois Baclesse; Comite Sein, Caen

28041

Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid

28050

Centro Integral Oncologico Clara Campal (CIOCC); Dirección Médica, Madrid

30625

University of Hannover; Medical School, Hanover

31059

Institut Universitaire du Cancer - Oncopole Toulouse (IUCT-O), Toulouse

34298

Institut régional du Cancer Montpellier, Montpellier

45122

Universitaetsklinikum Essen; Westdeutsches Tumorzentrum; Innere Klinik (Tumorforschung), Essen

46010

Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia

69120

Nationales Centrum für Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg, Heidelberg

75231

Institut Curie; Oncologie Medicale, Paris

08003

Hospital del Mar; Servicio de Oncologia, Barcelona

08035

Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY